Authors
Latest:
New Patent-Defense Path for PharmaInter Partes Review can potentially offer a more economical and streamlined litigation strategy for pharma and biotech players, writes David Dalke.
Latest:
Planning for the Future of SerializationCompliance with the new traceability requirements necessitates an understanding of how and when to begin implementing changes in an ever-evolving industry.
Latest:
Crowdfunding: The Open-Source Option Against Capital CrunchIs crowdfunding an attractive alternative to finance pharma and biotech start-ups? Seth R. Ogden and M. Andrew Holtman report.
Latest:
Crowdfunding: The Open-Source Option Against Capital CrunchIs crowdfunding an attractive alternative to finance pharma and biotech start-ups? Seth R. Ogden and M. Andrew Holtman report.
Latest:
Executive Coaching: Transforming Big Pharma from WithinDefining the critical coaching steps necessary for top managers to realize their potential in an industry undergoing significant restructuring of human and financial capital.
Latest:
Brexit Report: What's Next for the Industry?As the UK exits the European Union, the pharmaceutical and life sciences industries should prepare for changes by identifying key business issues, mitigating risks and creating plans for multiple scenarios.
Latest:
The Human Microbiome—Our Body's Secret WeaponNew research on the role of microbes in fighting disease is transforming the way medicine views bacteria, writes Lee Jones.
Latest:
Ireland’s Role in the European Union’s Evolving Pharmaceutical SectorRory Mullen outlines Ireland’s importance to multinational pharma in the changing EU landscape.
Latest:
The Fruits of Comparative EffectivenessNew CER tools grant payers the evidence they need to control drug costs
Latest:
Plant ManagementWe ask three managers building Greenfield plants to rationalize and defend their decisions
Latest:
FDA Feels Pinch of House Funding CutsThe House Appropriations Committee released the fiscal year 2013 Agriculture Appropriations bill, which, sets proposed spending levels for FDA as well as for other programs.
Latest:
AI-based Social Listening as Aid to PharmacovigilanceHow artificial intelligence can help pharma filter out the online noise when monitoring for safety signals on the web.
Latest:
Country Report: The Czech RepublicAlthough still tightly regulated, healthcare industry stakeholders-buoyed by regulatory reforms aimed at increasing patient access to innovative new therapies-are cautiously optimistic that the Czech Republic will further close the gap with Western Europe.
Latest:
The Fruits of Comparative EffectivenessNew CER tools grant payers the evidence they need to control drug costs
Latest:
A Forecasting Rx for Pharmacy Benefit ManagersBuilding an effective drug forecasting model today requires a revamped approach.
Latest:
The '3S' Framework for Post-Deal Growthpartnerships, big pharma, data exchange, Business Development, M&A, Business Strategy, information exchange, dealmaking, Rebecca Ashkenazy, Alex Chang, Cyndi Green, Ted Miller, Christine de los Reyes, targeted medicine, R&D productivity
Latest:
The '3S' Framework for Post-Deal Growthpartnerships, big pharma, data exchange, Business Development, M&A, Business Strategy, information exchange, dealmaking, Rebecca Ashkenazy, Alex Chang, Cyndi Green, Ted Miller, Christine de los Reyes, targeted medicine, R&D productivity
Latest:
The '3S' Framework for Post-Deal Growthpartnerships, big pharma, data exchange, Business Development, M&A, Business Strategy, information exchange, dealmaking, Rebecca Ashkenazy, Alex Chang, Cyndi Green, Ted Miller, Christine de los Reyes, targeted medicine, R&D productivity
Latest:
The '3S' Framework for Post-Deal Growthpartnerships, big pharma, data exchange, Business Development, M&A, Business Strategy, information exchange, dealmaking, Rebecca Ashkenazy, Alex Chang, Cyndi Green, Ted Miller, Christine de los Reyes, targeted medicine, R&D productivity
Latest:
The '3S' Framework for Post-Deal Growthpartnerships, big pharma, data exchange, Business Development, M&A, Business Strategy, information exchange, dealmaking, Rebecca Ashkenazy, Alex Chang, Cyndi Green, Ted Miller, Christine de los Reyes, targeted medicine, R&D productivity
Latest:
The Changing Landscape of Digital TrialsRichard Young, Vice President of Strategy, Vault CDMS and Tim Davis, Vice President of Strategy, MyVeeva for Patients, discuss the future of digital trials and their impact in the industry.
Latest:
The Pharma Leadership Challenge: Thawing the “Frozen” Middle ManagersThe challenge for senior leadership is to enable the layers of middle management to work to their full potential. Mike Straw argues that ‘failing fast’ should become the new mantra if pharma is going to drive greater innovation and creativity.
Latest:
Market Access in UkraineOn September 16, 2014, the Ukrainian and European parliaments ratified the EU–Ukraine Association Agreement (AA), providing for harmonization of many spheres of Ukrainian legislation with EU policy.
